Pharmacological Studies with New Liposome-Entrapped Cisplatin Derivatives
Therapy for disseminated human cancer is limited by the low degree of tumor selectivity with the antitumor agents currently available. The development of succesful ways to target cytotoxic agents to tumor sites is, therefore, important but, as yet, the approach is still in its infancy. Different types of drug carriers have been considered for that purpose and, among those, liposomes continue to attract significant attention. During the last few years, there has been steady progress in the liposome field, mainly in trying to solve some of the well recognized limitations of lipid vesicles as drug carriers in general, and as carriers of antitumor agents in particular: formulation, scaling up, and tumor targeting properties.
KeywordsHepatic Artery Lipid Bilayer Platinum Compound LoVo Cell Multilamellar Vesicle
Unable to display preview. Download preview PDF.
- 6.Perez-Soler R, LY Yang, B Drewinko, J Lautersztain, AR Khokhar: Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum (II) with entrapment of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar vesicles. Cancer Res 48:4509–4512, 1988.PubMedGoogle Scholar
- 9.Perez-Soler R, AR Khokhar, J Lautersztain, PA Mitchell, KL Schmidt: Ultrastructural and freeze fracture localization of multilamellar liposomes containing a lipophilic cisplatin analogue in normal tissues and liver metastases of M5076 reticulosarcoma. Cancer Drug Deliv 4:75–88, 1987.PubMedCrossRefGoogle Scholar
- 11.Khokhar AR, Wright K, ZH Siddik, R Perez-Soler: Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Cancer Chemother Pharmacol 22:223–227, 1988.PubMedCrossRefGoogle Scholar